Battelle and pharmaceutical company Zogenix will present new data about the benefits and feasibility of needle-free injection technology in subcutaneously administered biologics at a national medical industry forum this week in San Diego.
The organizations will unveil the findings at the American Association of Pharmaceutical Scientists National Biotechnology Conference Monday through Wednesday, Battelle and Zogenix said Monday.
“We believe the AAPS National Biotechnology Conference will be an excellent forum to introduce the DosePro system to potential biopharmaceutical partners,” said John Turanin, a Zogenix vice president and general manager.
Zogenix’s DosePro, a needle-free self-injectable system, is compatible with monoclonal antibodies formulations and other biologic formulation viscosities, according to the companies.
MedImmune LLC, a worldwide biologics research and development arm of AstraZeneca and Zogenix, co-authored two of the four posters set to display the data.
Battelle and Zogenix co-authored the other two posters.